Lucht R E, Knopp M V, Brix G
Division of Medical Radiation Hygiene, Institute of Radiation Hygiene, Federal Office for Radiation Protection, Neuherberg, Germany.
Magn Reson Imaging. 2001 Jan;19(1):51-7. doi: 10.1016/s0730-725x(01)00222-3.
The aim of this study was to test the performance of artificial neural networks for the classification of signal-time curves obtained from breast masses by dynamic MRI. Signal-time courses from 105 parenchyma, 162 malignant, and 102 benign tissue regions were examined. The latter two groups were histopathologically verified. Four neural networks corresponding to different temporal resolutions of the signal-time curves were tested. The resolution ranges from 28 measurements with a temporal spacing of 23s to just 3 measurements taken 1.8, 3, and 10 minutes after contrast medium administration. Discrimination between malignant and benign lesions is best if 28 measurement points are used (sensitivity: 84%, specificity: 81%). The use of three measurement points results in 78% sensitivity and 76% specificity. These results correspond to values obtained by human experts who visually evaluated signal-time curves without considering additional morphologic information. All examined networks yielded poor results for the subclassification of the benign lesions into fibroadenomas and benign proliferative changes. Neural networks can computationally fast distinguish between malignant and benign lesions even when only a few post-contrast measurements are made. More precise specification of the type of the benign lesion will require incorporation of additional morphological or pharmacokinetic information.
本研究的目的是测试人工神经网络对动态磁共振成像(MRI)获取的乳腺肿块信号-时间曲线进行分类的性能。研究检查了105个实质组织区域、162个恶性组织区域和102个良性组织区域的信号-时间过程。后两组经组织病理学证实。测试了与信号-时间曲线不同时间分辨率相对应的四个神经网络。分辨率范围从28次测量(时间间隔为23秒)到仅在注射造影剂后1.8分钟、3分钟和10分钟进行的3次测量。如果使用28个测量点,恶性和良性病变之间的区分效果最佳(敏感性:84%,特异性:81%)。使用三个测量点时,敏感性为78%,特异性为76%。这些结果与人类专家在不考虑其他形态学信息的情况下对信号-时间曲线进行视觉评估所获得的值相当。所有检查的网络对将良性病变细分为纤维腺瘤和良性增生性改变的结果都很差。即使只进行了少量造影剂注射后的测量,人工神经网络也能在计算上快速区分恶性和良性病变。要更精确地确定良性病变的类型,需要纳入额外的形态学或药代动力学信息。